Eli Lilly LLY and Merck MRK are leading global pharmaceutical companies with blockbuster drug portfolios and promising pipelines. Both have a strong presence in oncology, immunology and neuroscience. Lilly has established a leadership position in cardiometabolic health, with its GLP-1 drugs Mounjaro and Zepbound contributing around 65% of total revenues. Merck, meanwhile, relies heavily on oncology, with its blockbuster cancer drug Keytruda accounting for around 55% of pharmaceutical sales. Which stock offers a more attractive investment opportunity today? A comparison of their fundamentals, growth prospects and key challenges can help investors assess their relative appeal.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.